Forgot Username
 Forgot Password

Participant Information

  • Ulcerative Colitis Study

Ulcerative Colitis Study

Principal Investigator: Cristina Hill Jensen

Sub-Investigators: Julie Kittelsrud, CNP; Susan Weaver, CNP

Study Coordinator: Gail Syverson, RN

Study Description: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis

Overview: The purpose of this study is to test how well and how safe the study drug is in treating individuals with active, mild to moderate Ulcerative Colitis. The study drug will be compared to subjects taking a placebo pill (a pill with no active ingredients).

Participants in this study will receive—at no cost—the investigational drug/placebo, as well as any medical treatment/procedures not considered standard of care. There will be no out-of-pocket costs for any special lab tests, the study doctors’ time, or study drugs required only for this research study.

Inclusion Criteria:

  • Men and women who are age 18 or older
  • Have mild to moderate ulcerative colitis
  • Have adequate kidney, liver, and bone marrow function

Exclusion Criteria:

  • Women who are breastfeeding, pregnant, or planning to become pregnant
  • Have been diagnosed with Crohn’s disease
  • Have an active C. diff infection


Contact: Gail Syverson, RN

Phone: (605) 322-3075


Currently Enrolling Studies

Clinical Drug Research
The Avera Research Institute offers a variety of clinical trials on disease treatment and prevention, as well as health improvement.

Current clinical trials

Clinical Cancer Research
Avera has a robust cancer research program. Visit the link below to view a list of cancer trials currently open to enrollment.

Current cancer trials

Avera Institute for Human Genetics

The Avera Institute for Human Genetics (AIHG) is the premier genetics laboratory in the region.

Avera IHG details

National Institute of Mental Health Outreach Partnership Program

View updates regarding our partnership program and other available resources.